SMO and neoplasm: We identified a set of well-known ligands expressed by immune and stromal populations with known EMT-inducing activity including WNT5A, WNT3A, TGFB1, TGFB2, FGF2, IL6, CXCL8, HGF, and FGF1 (59–66) as well as EMT markers or drivers in tumor cells including JAK1, AKT2, SMO, CTNNB1, SMAD2, and NFKB2 (61–69).